TABLE 1.
ADR incidence of andrographolide derivative injections.
| Andrographolide derivative injections | Number of ADRs with CTCAE grading | Total number of ADRs | ADR incidence | Dosage (whether according to instructions) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| G1 | G2 | G3 | G4 | G5 | Unclear | Lower | Yes | Higher | Unclear | |||
| Andrographolide sulfonate (AS, trade name: Xiyanping injection) | 60 | 9 | 1 | 0 | 0 | 128 | 198 | 5.48% [4.47%, 6.72%] | 12 | 174 | 6 | 6 |
| Potassium sodium dehydroandrographolide succinate (PSDS, trade name: Yanhuning injection) | 34 | 16 | 0 | 0 | 0 | 96 | 146 | 3.69% [2.59%, 4.94%] | 0 | 15 | 6 | 125 |
| Potassium dehydroandrogrpholide succinate (PDS, trade name: Chuanhuning injection) | 9 | 0 | 0 | 0 | 0 | 17 | 26 | 5.33% [3.68%, 7.72%] | 0 | 13 | 0 | 13 |
| Andrographolide sodium bisulfite (ASB, trade name: Lianbizhi injection) | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0.67% (1/150) | 0 | 0 | 0 | 1 |
| Andrographis paniculata (AP, trade name: Chuanxinlian injection) | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 3.45% (2/58) | 0 | 0 | 0 | 2 |
| Other a | 0 | 0 | 0 | 0 | 0 | 6 | 6 | LiangRJ 1998 Liang, (1998): 15.00% (6/40) | 0 | 0 | 0 | 6 |
| 4 | 0 | 0 | 0 | 0 | 0 | 4 | YuCC 2010 Yu et al. (2010): 1.54% (4/260) | 0 | 0 | 0 | 4 | |
a
In these 2 articles, the authors only reported that they used injections containing andrographolide, and did not specify the name of the injection, so the active ingredients of these injections were unknown.